Analys

NextCell Pharma (Q4 2024/2025 update): ProTrans-Young readout in Q3 2026 - Redeye

{newsItem.title}

Redeye Publicerad: 06 Nov 09:23

NextCell Pharma

Redeye updates on NextCell following its Q4 report, which showed figures largely aligning with estimates. All patients in the ProTrans-Young trial are now dosed, setting up for a readout after summer 2026, which is the major catalyst ahead for the company.

Länk till analysen i sin helhet: https://www.redeye.se/research/1135531/nextcell-pharma-q4-2024-2025-update-protrans-young-readout-in-q3-2026?utm_source=finwire&utm_medium=RSS

Nyheter om NextCell Pharma

Läses av andra just nu

Om aktien NextCell Pharma

Senaste nytt